A subarachnoid hemorrhage is a medical emergency. Immediate treatment is needed to help reduce the risk for lifelong brain damage. The main goal is to stop the bleeding and prevent rebleeding.

The use of dynamic 18F-FDG PET to determine changes in tumor metabolism requires tumor and plasma time–activity curves. Because arterial sampling is invasive and laborious, our aim was to validate ...

A Hipertensão Arterial Resistente (HAR) é definida quando a Pressão Arterial (PA) permanece acima das metas recomendadas com o uso de três fármacos anti-hipertensivos com ações sinérgicas em doses ...

Pulmonary arterial hypertension (PAH) is a rare but lethal disorder caused by several pathological changes in the pulmonary vasculature. There is endothelial cell dysfunction characterized by ...

Introduction Identifying acute hypercapnic respiratory failure is crucial in the initial management of acute exacerbations of COPD. Guidelines recommend obtaining arterial blood samples but these are ...

Leg amputation rates caused by arterial disease are four times as high in the most disadvantaged areas in England. The new study, from the University of Sheffield, also found patients living in the ...

Introdução. Na medicina moderna, a análise de gasometria arterial tornou-se uma das investigações laboratoriais mais comuns como parte da avaliação respiratória de pacientes com doenças agudas. 1 ...

Arterial stiffness is a growing epidemic associated with increased risk of cardiovascular events, dementia, and death. Decreased compliance of the central vasculature alters arterial pressure and flow ...

Methods Children diagnosed with arterial ischaemic stroke between 2003 and 2012 were assessed at least 1 year poststroke using the parent–proxy report versions of the Pediatric Quality of Life ...

Um tratamento inovador para hipertensão arterial pulmonar, o sotatercepte, chega ao Brasil, prometendo reduzir em 84% o risco de morte e melhorar a qualidade de vida dos pacientes. A condição ...

Liquidia announces FDA approval and commercial launch of YUTREPIA for treating pulmonary arterial hypertension and PH-ILD. Quiver AI Summary. Liquidia Corporation has announced that its inhalation ...